Lupin reported a 22 per cent drop in net profit to ₹1,155 crore for the September quarter on Wednesday. Revenue grew to ₹7,827 crore, but an exceptional item impacted earnings. Managing Director Nilesh Gupta said, "We delivered a strong first half of FY27, underpinned by solid growth across key markets."
Homegrown pharma major Lupin on Wednesday posted a 22.19 per cent decline in consolidated net profit to ₹1,155.30 crore in the September quarter, dragged down by an exceptional item.
The company had posted a net profit of ₹1,484.83 crore in the corresponding period of the previous fiscal year, it said in a regulatory filing to the exchanges.
Revenue from operations was ₹7,827.26 crore during the quarter under review, up from ₹7,047.51 crore in the year-ago period, it said.
Lupin's total expenses also rose to ₹6,374.46 crore during the quarter from ₹5,130.54 crore in the same period last year.
During the April-September period in FY27, Lupin's net profit declined 4.95 per cent to ₹2,572.28 crore from ₹2,706.29 crore a year earlier, the filing said.
SBI Q2FY27 results: Net profit rose 14% on loan growth, stake sales
Will only pursue selective acquisitions, says Marico CEO Saugata Guptapremium
ITC's cigarette business likely to remain under pressure in H2FY27premium
NSE Q2FY27 results: Consolidated net profit rises 23% YoY to ₹2,578 crore
Samhi Hospitality Q2 net profit falls 59% to ₹41 cr despite revenue rise
During the six months ended September 30, 2026, Lupin Pharmaceuticals Inc USA, a wholly owned subsidiary of the Group, settled one of the ongoing antitrust matte₹for ₹316.28 crore (USD 35.8 million) without admission of liability or wrongdoing, the drugmaker said in the filing.
The group continues to carry the remaining provision towards future settlements related to similar cases, it added.
Meanwhile, the company's US sales during the September quarter are at ₹3,020.2 crore, up 9.3 per cent compared to ₹2,762.4 crore a year earlier, the company said.
Lupin continues to be the third-largest pharmaceutical player in both the US generic market and US total market by prescriptions as per IQVIA Quarter September 2026, the release noted.
India sales for Q2 FY27 were ₹2,383.6 crore, up 14.7 per cent compared to ₹2,077.7 crore in Q2 FY26, accounting for 31 per cent of Lupin's global sales, the release added.
Lupin Managing Director Nilesh Gupta said, "We delivered a strong first half of FY27, underpinned by solid growth across key markets and sustained profitability. While we remain mindful of near-term challenges, we are confident in our long-term growth prospects, supported by the strength of our portfolio, continued investments in R&D and commercial capabilities, and our unwavering focus on disciplined execution.